Regulatory-Ready, Data-Driven Purification Through LC-MS-Based Host Cell Protein Analysis

Regulators increasingly emphasize total process understanding from development to commercial scale. With 75% of FDA rejections tied to CMC shortcomings, LC-MS-based impurity analysis is key to a regulatory-ready, data-driven purification strategy